Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently updated its clinical study ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte’s second quarter was marked by broad-based strength across its commercial portfolio, reflected in a significant ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Stamoulis joins Mallinckrodt from Incyte, a leading biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. In addition ...

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with ...

Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and ...

Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations. Click here to find out why SNDX stock is a Hold.